Literature DB >> 11072208

Cervical cancer screening in Germany.

U Schenck1, L von Karsa.   

Abstract

Cervical cancer is one of the target cancers covered by the statutory German cancer screening programme which was introduced in West Germany in 1971 and expanded to the eastern part of the country in 1991. Women covered by statutory health insurance (over 90% of the female population) are eligible to receive an annual cervical examination including a Papanicolaou (PAP) smear beginning at age 20 years. Annual uptake currently slightly exceeds 50% of the eligible population. Shortly after implementation of the national screening programme in the early 1970s the incidence of invasive cervical cancer decreased moderately and the incidence of cervical carcinoma in situ increased substantially in the state of Saarland. These observations would be expected as a result of a cervical cancer screening programme with substantial uptake. Although quality assurance guidelines for cervical cancer screening have been adopted and updated since the inception of the screening programme, only minor changes have been made in the cross-sectional programme documentation. Implementation of population-based documentation and evaluation of screening activities is currently being developed for the German cancer screening programme in pilot studies implementing the European guidelines on the quality assurance of mammography screening. After demonstration of feasibility and effectiveness, improvements in the quality management of breast cancer screening will subsequently be applied to the cervical cancer screening programme.

Entities:  

Mesh:

Year:  2000        PMID: 11072208     DOI: 10.1016/s0959-8049(00)00313-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Epidemiological aspects of cancer screening in Germany.

Authors:  Nikolaus Becker
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-14       Impact factor: 4.553

2.  Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.

Authors:  Thomas Iftner; Sven Becker; Klaus-Joachim Neis; Alejandra Castanon; Angelika Iftner; Barbara Holz; Annette Staebler; Melanie Henes; Katharina Rall; Juliane Haedicke; Claus Hann von Weyhern; Andreas Clad; Sara Brucker; Peter Sasieni
Journal:  J Clin Microbiol       Date:  2015-05-27       Impact factor: 5.948

3.  Socio-demographic characteristics of participation in the opportunistic German cervical cancer screening programme: results from the EPIC-Heidelberg cohort.

Authors:  David Seidel; Nikolaus Becker; Sabine Rohrmann; Katharina Nimptsch; Jakob Linseisen
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-08       Impact factor: 4.553

4.  Early detection of cervical carcinomas: finding an overall approach.

Authors:  Nicolas Wentzensen; Stefanie J Klug
Journal:  Dtsch Arztebl Int       Date:  2008-09-12       Impact factor: 5.594

5.  Study-based evaluation of the Abbott RealTime High Risk HPV test in comparison to the HC2 HR HPV test in women aged ≥30 years using residual LBC ThinPrep specimens.

Authors:  Thomas Iftner; Lisa Wang; Angelika Iftner; Barbara Holz; Juliane Haedicke-Jarboui; Nathalie Iftner; Reinhard von Wasielewski; Peter Martus; Gerd Boehmer
Journal:  BMC Infect Dis       Date:  2016-11-11       Impact factor: 3.090

6.  HPV-vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level.

Authors:  Emma Altobelli; Leonardo Rapacchietta; Valerio F Profeta; Roberto Fagnano
Journal:  Cancer Med       Date:  2019-04-16       Impact factor: 4.452

7.  Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model.

Authors:  Deniz Schobert; Vanessa Remy; Oliver Schoeffski
Journal:  Health Econ Rev       Date:  2012-09-25

8.  Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients.

Authors:  K-U Petry; S Menton; M Menton; F van Loenen-Frosch; H de Carvalho Gomes; B Holz; B Schopp; S Garbrecht-Buettner; P Davies; G Boehmer; E van den Akker; T Iftner
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

9.  A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.

Authors:  Gerd Boehmer; Lisa Wang; Angelika Iftner; Barbara Holz; Juliane Haedicke; Reinhard von Wasielewski; Peter Martus; Thomas Iftner
Journal:  BMC Infect Dis       Date:  2014-12-09       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.